BDTX实时信号 | 通过Getagraph.com最大化利润

购买 107605 min ago

@ $4.67

发出时间: 15 Feb 2024 @ 02:53

回报率: 26.12%

上一信号: Feb 14 - 04:50

上一信号: 出售

回报率: 11.73 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors...

Stats
今日成交量	566 432
平均成交量	630 422
市值	309.40M
EPS	$0 ( 2024-03-14 )
下一个收益日期	( $-0.440 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.13
ATR14	$0.0160 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Campbell Shannon	Buy	61 100	Stock Option (Right to Buy)
2024-04-10	Raman Prakash	Buy	61 100	Stock Option (Right to Buy)
2024-04-10	Campbell Shannon	Buy	0
2024-04-10	Raman Prakash	Buy	0
2024-03-15	Behbahani Ali	Buy	3 166	Common Stock

INSIDER POWER
98.88
Last 97 transactions
Buy: 11 965 700 \| Sell: 275 000

音量相关性

長: 0.36 (neutral)

短: -0.88 (strong negative)

Signal:(49.388) Neutral

Black Diamond 相关性

10 最正相关
SVAC	0.972
RMRM	0.952
TLGT	0.926
ACST	0.919
PXLW	0.916
FEYE	0.898
BLZE	0.877
IMAB	0.877
VVOS	0.877
TMTS	0.875

10 最负相关
AMRB	-0.962
NETE	-0.958
MMAC	-0.951
GOODM	-0.903
GLADL	-0.898
SRAC	-0.881
QELL	-0.878
ROCR	-0.874
LWAC	-0.872
RAVN	-0.864

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Black Diamond 相关性 - 货币/商品

0.92
( very strong )

0.79
( moderate )

0.00
( neutral )

0.75
( moderate )

-0.43
( neutral )

-0.88
( strong negative )

Black Diamond 财务报表

Annual	2023
营收:	$0
毛利润:	$-437 000 (0.00 %)
EPS:	$-1.880

FY	2023
营收:	$0
毛利润:	$-437 000 (0.00 %)
EPS:	$-1.880

FY	2022
营收:	$0
毛利润:	$-3.24M (0.00 %)
EPS:	$-2.33

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.00347

Financial Reports:

No articles found.

Black Diamond

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.